These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 34073147)

  • 41. Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.
    Kizilbash SH; Gupta SK; Chang K; Kawashima R; Parrish KE; Carlson BL; Bakken KK; Mladek AC; Schroeder MA; Decker PA; Kitange GJ; Shen Y; Feng Y; Protter AA; Elmquist WF; Sarkaria JN
    Mol Cancer Ther; 2017 Dec; 16(12):2735-2746. PubMed ID: 28947502
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Poly(ADP-ribose) polymerase-1 regulates the mechanism of irradiation-induced CNE-2 human nasopharyngeal carcinoma cell autophagy and inhibition of autophagy contributes to the radiation sensitization of CNE-2 cells.
    Zhou ZR; Zhu XD; Zhao W; Qu S; Su F; Huang ST; Ma JL; Li XY
    Oncol Rep; 2013 Jun; 29(6):2498-506. PubMed ID: 23563481
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
    Li Y; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterisation of Deubiquitylating Enzymes in the Cellular Response to High-LET Ionizing Radiation and Complex DNA Damage.
    Carter RJ; Nickson CM; Thompson JM; Kacperek A; Hill MA; Parsons JL
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):656-665. PubMed ID: 30851349
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting PARP and autophagy evoked synergistic lethality in hepatocellular carcinoma.
    Zai W; Chen W; Han Y; Wu Z; Fan J; Zhang X; Luan J; Tang S; Jin X; Fu X; Gao H; Ju D; Liu H
    Carcinogenesis; 2020 May; 41(3):345-357. PubMed ID: 31175354
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology.
    Bruin MAC; Sonke GS; Beijnen JH; Huitema ADR
    Clin Pharmacokinet; 2022 Dec; 61(12):1649-1675. PubMed ID: 36219340
    [TBL] [Abstract][Full Text] [Related]  

  • 47. p21CDKN1A Regulates the Binding of Poly(ADP-Ribose) Polymerase-1 to DNA Repair Intermediates.
    Dutto I; Sukhanova M; Tillhon M; Cazzalini O; Stivala LA; Scovassi AI; Lavrik O; Prosperi E
    PLoS One; 2016; 11(1):e0146031. PubMed ID: 26730949
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
    Onstad M; Coleman RL; Westin SN
    Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
    Sun Y; Gallacchi D; Zhang EY; Reynolds SB; Robinson L; Malinowska IA; Chiou TT; Pereira AM; Li C; Kwiatkowski DJ; Lee PS; Yu JJ
    Am J Respir Cell Mol Biol; 2014 Dec; 51(6):738-49. PubMed ID: 24874429
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics.
    Engert F; Kovac M; Baumhoer D; Nathrath M; Fulda S
    Oncotarget; 2017 Jul; 8(30):48794-48806. PubMed ID: 27447864
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PARP-1 inhibition induces a late increase in the level of reactive oxygen species in cells after ionizing radiation.
    Cieślar-Pobuda A; Saenko Y; Rzeszowska-Wolny J
    Mutat Res; 2012 Apr; 732(1-2):9-15. PubMed ID: 22321899
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PARP-DNA trapping ability of PARP inhibitors jeopardizes astrocyte viability: Implications for CNS disease therapeutics.
    Sinha A; Katyal S; Kauppinen TM
    Neuropharmacology; 2021 Apr; 187():108502. PubMed ID: 33631119
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Proton and photon radiosensitization effects of niraparib, a PARP-1/-2 inhibitor, on human head and neck cancer cells.
    Wang L; Cao J; Wang X; Lin E; Wang Z; Li Y; Li Y; Chen M; Wang X; Jiang B; Zhang R; Sahoo N; Zhang X; Zhu XR; Myers JN; Frank SJ
    Head Neck; 2020 Sep; 42(9):2244-2256. PubMed ID: 32323895
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
    Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
    PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
    Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
    Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma.
    Fröhlich LM; Villar-Miyar A; Heintze T; Sauer B; Schittek B
    Int J Cancer; 2024 Jul; 155(2):203-210. PubMed ID: 38619111
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
    Murai J; Huang SY; Renaud A; Zhang Y; Ji J; Takeda S; Morris J; Teicher B; Doroshow JH; Pommier Y
    Mol Cancer Ther; 2014 Feb; 13(2):433-43. PubMed ID: 24356813
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of onconase in the therapeutic potential of PARP inhibitors in A375 malignant melanoma cells.
    Raineri A; Prodomini S; Fasoli S; Gotte G; Menegazzi M
    Biochem Pharmacol; 2019 Sep; 167():173-181. PubMed ID: 31185226
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.